Fiche publication
Date publication
juin 2019
Journal
The Journal of infectious diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
Tous les auteurs :
Olbrich A, Wardemann H, Böhm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J
Lien Pubmed
Résumé
Neutralizing antibodies can prevent hepatitis C virus (HCV) infection, one of the leading causes of cirrhosis and liver cancer. Here, we characterized the immunoglobulin repertoire of memory B cell antibodies against a linear epitope in the central front layer of HCV envelope (E2) (aa483-499) in patients that were infected in a single-source outbreak. A reverse transcriptase (RT)-PCR based immunoglobulin gene cloning and recombinant expression approach was applied to express monoclonal antibodies from HCV E2-peptide-binding IgG+ memory B cells. We identified highly mutated antibodies with neutralizing effect in vitro against different genotype isolates sharing similar gene features. Our data confirm the importance of VH1-69 usage for neutralizing activity. The data offers a promising basis for vaccine research and the use of anti-E2 antibodies as a mean of passive immunization.
Mots clés
HCV, HCV envelope (E2) protein, anti-D cohort, memory B cells, neutralizing antibodies
Référence
J. Infect. Dis.. 2019 Jun 4;:
